Clinical Trial Update: Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 safety, pharmacokinetics, and pharmacodynamics study of BMS-866949 in healthy subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• BMS-866949

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Depression | Phase 1 | Status: COMPLETED